Scientific Program

Conference Series Ltd invites all the participants across the globe to attend World Heart Congress Osaka, Japan.

Day 1 :

Keynote Forum

Kazutaka Aonuma

Director, Cardiovascular Division, Tsukuba University Hospital, Japan

Keynote: Current status and the future direction of atrial fibrillation ablation

Time : 09:00-09:50

OMICS International Heart Congress 2017 International Conference Keynote Speaker Kazutaka Aonuma photo
Biography:

Kazutaka Aonuma is the Director of Cardiovascular Division, Tsukuba University Hospital and Professor of Medicine, University of Tsukuba, Graduate School of Comprehensive Human Sciences, Tsukuba, Japan. He is also the President of Japanese Heart Rhythm Society 2016 and Editorial Board Member of Journal of Arrhythmia- Elsevier.

Abstract:

Electrical pulmonary vein isolation (PVI) by ablating encircle the pulmonary vein has become a standardized treatment technique for paroxysmal atrial fibrillation (PAF). The data showing sufficient long-term results has proven to be superior to antiarrhythmic therapy for long-term period. More recently, many one shot techniques such as cryo-balloon and hot-balloon has also become established as an alternative therapeutic option. However; PVI alone also appears to be insufficient for treating persistent AF (pers. AF), with disappointing long-term results. Therefore, additional ablation strategies targeting the modification and/or elimination of the AF-sustaining atrial substrate have been used including ablation of complex fractionated atrial electrograms (CFAEs), deployment of linear lesions in the left atrium (LA), and other additional ablation techniques have been tried for many year. In this key-note lecture, the author will review the history of ablation of PAF, and also pers. AF, and will discuss about the future direction of the treatment atrial fibrillation.

Electrical pulmonary vein isolation (PVI) by ablating encircle the pulmonary vein has become a standardized treatment technique for paroxysmal atrial fibrillation (PAF). The data showing sufficient long-term results has proven to be superior to antiarrhythmic therapy for long-term period. More recently, many one shot techniques such as cryo-balloon and hot-balloon has also become established as an alternative therapeutic option. However; PVI alone also appears to be insufficient for treating persistent AF (pers. AF), with disappointing long-term results. Therefore, additional ablation strategies targeting the modification and/or elimination of the AF-sustaining atrial substrate have been used including ablation of complex fractionated atrial electrograms (CFAEs), deployment of linear lesions in the left atrium (LA), and other additional ablation techniques have been tried for many year. In this key-note lecture, the author will review the history of ablation of PAF, and also pers. AF, and will discuss about the future direction of the treatment atrial fibrillation.

Keynote Forum

Yuji Matsuzawa

President ,International Atherosclerosis Society, Japan

Keynote: Visceral obesity, adiponectin and atherosclerosis

Time : 09:50-10:40

OMICS International Heart Congress 2017 International Conference Keynote Speaker Yuji Matsuzawa photo
Biography:

Yuji Matsuzawa has completed his graduation from Osaka University Medical School in 1966 and joined a research group of Lipid Research Laboratory at Osaka University in 1969. He became Professor of the second Department of Internal Medicine of Osaka University in 1991, until 2003 when he moved to Sumitomo Hospital as Director and Emeritus Professor of Osaka University. He has long worked on hyperlipidemia and obesity. He has discovered several novel disease entities such as "Autoimmune hyperchylomicrolemia" and "Hyper HDL cholesterolemia caused by CETP deficiency". He was also interested in body fat distribution with respect to morbidity. He developed the method for fat analysis using CT scan and established the concept named visceral fat syndrome in which cardiovascular risks cluster by visceral fat accumulation. He also investigated biological characteristics of adipose tissue and found that adipose tissue abundantly expressed bioactive substances. During these works, he discovered "adiponectin", which may be one of key players in the mechanism of obesity-related diseases. He is currently the President of International Atherosclerosis Society.

Abstract:

Although cholesterol, especially LDL-cholesterol has been considered to be a major risk factor of atherosclerosis and cholesterol lowering drugs such as statins has been valued highly for the prevention of cardiovascular disease in the clinical field of all over the world, residual risks such as non-cholesterol dyslipidemia, diabetes mellitus and hypertension, especially clustering of these risks has been also known to contribute to the occurrence of cardiovascular disease. Many epidemiological studies has revealed that obesity, especially visceral obesity may induce the development of diabetes mellitus, hypertension and dyslipidemia and the clustering of these risks may become strong risks of cardiovascular disease. In this lecture, I will show an important role of visceral fat accumulation in the development of a variety of obesity-related disease including cardiovascular disease based on our clinical studies using CT scan and also discuss the mechanism of these disorders by focusing on adipocytokines, adipose tissue-derived bioactive substances especially, adiponectin which was discovered from human adipose tissue by our group in 1995. Adiponectin is a unique collagen-like protein which has anti-diabetic, anti-atherogenic function as well as anti-inflammatory function. I would like to show that hypoadiponectinemia caused by visceral fat accumulation is a key mechanism of a variety of obesity-related diseases such as DM, hypertension and lipid disorders and also directly cardiovascular disease.